Company officials say its proprietary Tumor Treating Fields technology, marketed under the product name Optune, are a new tool in the war against cancer. Currently, the company has FDA approval for Glioblastoma, the deadliest form of brain cancer.
The results thus far have been impressive for Novocure. In December, data from the company’s pivotal phase 3 trial of its Optune device, published in the Journal of the American Medical Association, showed that Optune along with temozolomide chemotherapy significantly extended progression-free survival and overall survival compared to temozolomide alone in treating newly diagnosed glioblastoma.
MassDevice publisher Brian Johnson recently caught up with Bill Doyle, chairman, NovoCure to discuss the technology, the company’s origins and how its current concentration on glioblastoma is just the beginning for the company.
DeviceTalks West is just a few days away. Join more than 300 of your peers for a day of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.
Don’t miss out on this premier opportunity to come together and share perspectives with the best of the best in the industry.
Use code LASTCHANCE to save an additional 20%.